<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00000193 on 2013_09_26: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00000193">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00000193">&#8593; Current version of this study</a></div><h1>View of NCT00000193 on
  2013_09_26</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00000193</td>
</tr>
<tr>
<th>Updated:</th><td>2013_09_26</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Neurobiology of Opioid Dependence: 2 - 2</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>Neurobiology of Opioid Dependence: 2</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 2</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Double Blind</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Behavioral, subjective, measures of naloxone-preci</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Phsyiological, neuroendocrine measures of naloxone</td>
</tr>
<tr>
<th>Condition</th><td>
         Opioid-Related Disorders
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Gamma hydroxybutyric</div>
<p></p>
</td>
</tr>
<tr>
<th>Reference</th><td>
<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>
<div>MEDLINE: </div>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Withdrawn</td>
</tr>
<tr>
<th>Start date</th><td>
         1993-01
      </td>
</tr>
<tr>
<th>Last follow-up date</th><td>
         1998-01
      
      (Actual)
  </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         1998-01
      
      (Actual)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Please contact site for information.</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Male
         </td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Yale University</td>
</tr>
<tr>
<th>Organization study ID</th><td>NIDA-00191-2</td>
</tr>
<tr>
<th>Secondary ID</th><td>K20DA000191
      (US NIH Grant Number)
    </td>
</tr>
<tr>
<th>Secondary ID</th><td>
            K20-00191-2
         </td>
</tr>
<tr>
<th>Sponsor</th><td>
               Yale University
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               National Institute on Drug Abuse (NIDA)
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               Yale University
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Federal Government
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
